Kristina Daniunaite1, Sonata Jarmalaite2, Neringa Kalinauskaite1, Donatas Petroska3, Arvydas Laurinavicius3, Juozas R Lazutka1, Feliksas Jankevicius4. 1. Faculty of Natural Sciences, Vilnius University, Vilnius, Lithuania. 2. Faculty of Natural Sciences, Vilnius University, Vilnius, Lithuania. Electronic address: sonata.jarmalaite@gf.vu.lt. 3. Faculty of Medicine, Vilnius University, Vilnius, Lithuania; National Centre of Pathology, Vilnius, Lithuania. 4. Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Urology Centre, Vilnius University, Vilnius, Lithuania.
Abstract
PURPOSE: Patients with prostate cancer who have biochemical recurrence after curative therapy are at higher risk for distant metastasis and cancer specific death. Assessment of aberrant DNA methylation in urine might complement currently used clinical prognostic factors and serve as a noninvasive tool for early prediction of biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS: Promoter methylation of 7 genes was evaluated by methylation sensitive polymerase chain reaction in 149 prostate cancer tissues, 37 noncancerous prostate tissues and 17 benign prostatic hyperplasia samples. Quantitative polymerase chain reaction was used for DNA methylation analysis of the urine of 253 patients with prostate cancer and 32 with benign prostatic hyperplasia. RESULTS: In prostate cancer tissue the most frequently methylated genes were RASSF1, GSTP1 and RARB, which combined were positively identified in 85% of cases. These genes were also methylated in the urine of 60% of patients with prostate cancer. RASSF1 was methylated in 45% of prostate cancer urine samples with methylation intensity significantly higher in prostate cancer than in benign prostatic hyperplasia cases (p = 0.018). In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively). On multivariate analysis RASSF1 methylation together with pathological stage was the most significant predictor of biochemical recurrence in patients with Gleason score 6 tumors when analyzed in tissue and urine (p ≤0.001). CONCLUSIONS: Hypermethylation of RASSF1 in cancerous tissue and urine from patients with prostate cancer correlated with biochemical recurrence after radical prostatectomy. The prognostic potential of this biomarker deserves further investigation.
PURPOSE:Patients with prostate cancer who have biochemical recurrence after curative therapy are at higher risk for distant metastasis and cancer specific death. Assessment of aberrant DNA methylation in urine might complement currently used clinical prognostic factors and serve as a noninvasive tool for early prediction of biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS: Promoter methylation of 7 genes was evaluated by methylation sensitive polymerase chain reaction in 149 prostate cancer tissues, 37 noncancerous prostate tissues and 17 benign prostatic hyperplasia samples. Quantitative polymerase chain reaction was used for DNA methylation analysis of the urine of 253 patients with prostate cancer and 32 with benign prostatic hyperplasia. RESULTS: In prostate cancer tissue the most frequently methylated genes were RASSF1, GSTP1 and RARB, which combined were positively identified in 85% of cases. These genes were also methylated in the urine of 60% of patients with prostate cancer. RASSF1 was methylated in 45% of prostate cancer urine samples with methylation intensity significantly higher in prostate cancer than in benign prostatic hyperplasia cases (p = 0.018). In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively). On multivariate analysis RASSF1 methylation together with pathological stage was the most significant predictor of biochemical recurrence in patients with Gleason score 6 tumors when analyzed in tissue and urine (p ≤0.001). CONCLUSIONS: Hypermethylation of RASSF1 in cancerous tissue and urine from patients with prostate cancer correlated with biochemical recurrence after radical prostatectomy. The prognostic potential of this biomarker deserves further investigation.
Authors: Raimonda Kubiliūtė; Kristina Žukauskaitė; Algirdas Žalimas; Albertas Ulys; Rasa Sabaliauskaitė; Arnas Bakavičius; Arūnas Želvys; Feliksas Jankevičius; Sonata Jarmalaitė Journal: J Cancer Res Clin Oncol Date: 2021-10-23 Impact factor: 4.553
Authors: Kristina Stuopelyte; Rasa Sabaliauskaite; Arnas Bakavicius; Benedikta S Haflidadóttir; Tapio Visakorpi; Riina-Minna Väänänen; Chintan Patel; Daniel C Danila; Hans Lilja; Juozas R Lazutka; Albertas Ulys; Feliksas Jankevicius; Sonata Jarmalaite Journal: J Urol Date: 2020-02-18 Impact factor: 7.450
Authors: Alexey A Dmitriev; Eugenia E Rosenberg; George S Krasnov; Ganna V Gerashchenko; Vasily V Gordiyuk; Tatiana V Pavlova; Anna V Kudryavtseva; Artemy D Beniaminov; Anastasia A Belova; Yuriy N Bondarenko; Rostislav O Danilets; Alexander I Glukhov; Aleksandr G Kondratov; Andrey Alexeyenko; Boris Y Alekseev; George Klein; Vera N Senchenko; Vladimir I Kashuba Journal: Dis Markers Date: 2015-09-28 Impact factor: 3.434
Authors: Jakub Klacz; Piotr M Wierzbicki; Agata Wronska; Agnieszka Rybarczyk; Marcin Stanislawowski; Tomasz Slebioda; Agata Olejniczak; Marcin Matuszewski; Zbigniew Kmiec Journal: Int J Oncol Date: 2015-11-18 Impact factor: 5.650